Key facts
- This page summarizes Timothy L. Moore's Form 4 filing for Allogene Therapeutics, Inc. (ALLO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 05 Feb 2025, 16:14.
Timothy L. Moore - 03 Feb 2025 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)
- Reporting relationship
- Chief Technical Officer
- Issuer ticker
- ALLO
- Reported as of
- 03 Feb 2025
- Net transaction value
- -$25,216
- SEC form
- 4
- Accepted by SEC
- 05 Feb 2025, 16:14:49 UTC
- Prior SEC filing
- 06 Jun 2024
- Next SEC filing
- 20 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/Earl Douglas, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Timothy L. Moore filed Form 4 for Allogene Therapeutics, Inc. (ALLO) on 05 Feb 2025.
Change
- Previous filing in this sequence was filed on 06 Jun 2024.
- Current net transaction value: -$25,216.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALLO
transaction
Common Stock
Sale
- Transaction value
- $25,216
- Shares
- -14,746
- Change %
- -5.6%
- Price
- $1.71
- Shares after
- 250,713
- Date
- 03 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.715, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with in the rage set forth above.
SEC remarks
Exhibits: Power of Attorney